Elevated plasma concentration of NO and cGMP may be responsible for the decreased platelet aggregation and platelet leukocyte conjugation in platelets hypo-responsive to catecholamines

References

• Xiang YZ, Kang LY, Gao XM, Shang HC, Zhang JH, Zhang BL. Strategies for antiplatelet target and agents. Thromb Res 2008; 123: 35–49
   PubMed Web of Science ®Google Scholar
• Elwood PC, Renaud S, Sharp DS, Beswick AD, O'Brien JR, Yarnell JW. Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. Circulation 1991; 83: 38–44
   PubMed Web of Science ®Google Scholar
• Anfossi G, Trovati M. Role of catecholamines in platelet function: Pathophysiological and clinical significance. Eur J Clin Invest 1996; 26: 353–370
   PubMed Web of Science ®Google Scholar
• Gawaz M, Langer H, May AE. Platelet in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378–3384
   PubMed Web of Science ®Google Scholar
• Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood 1997; 89: 1270–1278
   PubMed Web of Science ®Google Scholar
• Li N, Goodall AH, Hjemdahl P. Efficient flow cytometric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. Cytometry 1999; 35: 154–161
   PubMedGoogle Scholar
• Zeller JA, Lenz A, Eschenfelder CC, Zunker P, Deuschl G. Platelet-leukocyte interaction and platelet activation in acute stroke with and without preceding infection. Arterioscler Thromb Vasc Biol 2005; 25: 1519–1523
   PubMed Web of Science ®Google Scholar
• Pamuk GE, Vural O, Turgut B, Demir M, Umit H, Tezel A. Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: A comparative study. Am J Hematol 2006; 81: 753–759
   PubMed Web of Science ®Google Scholar
• Izzi B, Pampuch A, Costanzo S, Vohnout B, Iacoviello L, Cerletti C, de Gaetano G. Determinants of platelet conjugate formation with polymorphonuclear leukocytes or monocytes in whole blood. Thromb Haemost 2007; 98: 1276–1284
   PubMed Web of Science ®Google Scholar
• Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: Its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 1999; 81: 1–7
   PubMed Web of Science ®Google Scholar
• Cerletti C, Evangelista V, de Gaetano G. P-selectin-beta 2-integrin cross-talk: A molecular mechanism for polymorphonuclear leukocyte recruitment at the site of vascular damage. Thromb Haemost 1999; 82: 787–793
   PubMed Web of Science ®Google Scholar
• Martins Pda C, Zwaginga CJJ. Leukocyte-platelet aggregates: New particles reflecting and effecting cardiovascular disease. Thromb Haemost 2005; 94: 1120–1121
   PubMed Web of Science ®Google Scholar
• Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454–456
   PubMed Web of Science ®Google Scholar
• Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986; 250: H822–H827
   PubMed Web of Science ®Google Scholar
• Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci 1991; 88: 4651–4655
   PubMed Web of Science ®Google Scholar
• Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res 1993; 27: 1380–1382
   PubMed Web of Science ®Google Scholar
• Radomski MW, Palmer RM, Moncada S. Characterization of the L-arginine: Nitric oxide pathway in human platelets. Br J Pharmacol 1990; 101: 325–328
   PubMed Web of Science ®Google Scholar
• Massberg S, Sausbier M, Klatt P, Bauer M, Pfeifer A, Siess W, Fässler R, Ruth P, Krombach F, Hofmann F. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′,5′-monophosphate kinase I. J Exp Med 1999; 189: 1255–1264
   PubMed Web of Science ®Google Scholar
• Riba R, Sharifi M, Farndale RW, Naseem KM. Regulation of platelet guanyly cyclase by collagen: Evidence that glycoprotein VI mediates platelet nitric oxide synthesis in response to collagen. Thromb Haemost 2005; 94: 395–403
   PubMed Web of Science ®Google Scholar
• Naseem KM, Riba R. Unresolved roles of platelet nitric oxide synthase. J Thromb Haemost 2008; 6: 10–19
   PubMed Web of Science ®Google Scholar
• Hines LM, Tabakoff B. WHO/ISBRA study on state and trait markers of alcohol use and dependence investigators. Platelet adenylyl cyclase activity: A biological marker for major depression and recent drug use. Biol Psychiatry 2005; 58: 955–962
   PubMed Web of Science ®Google Scholar
• Fisch A, Michael-Hepp J, Meyer J, Darius H. Synergistic interaction of adenylate cyclase ativators and nitric oxide donor SIN-1 on platelet cyclic AMP. Eur J Pharmacol 1995; 289: 455–461
   PubMed Web of Science ®Google Scholar
• Wang TY, Hussey CV, Sasse EA, Fobian JE. Human platelet aggregation and cAMP system–cAMP level, adenyl cyclase, phosphodiesterase. Ann Clin Lab Sci 1978; 8: 403–412
   PubMed Web of Science ®Google Scholar
• Feoktistov IA, Paul S, Hollister AS, Robertson D, Biaggioni I. Role of cyclic AMP in adenosine inhibition of intracellular calcium rise in human platelets. Comparison of adenosine effects on thrombin- and epinephrine-induced platelet stimulation. Am J Hypertens 1992; 5: 147S–153S
   PubMed Web of Science ®Google Scholar
• Bruce JI, Straub SV, Yule DI. Crosstalk between cAMP and Ca2+ signaling in non-excitable cells. Cell Calcium 2003; 34: 431–444
   PubMed Web of Science ®Google Scholar
• Kambayashi J, Shinoki N, Nakamura T, Ariyoshi H, Kawasaki T, Sakon M. Prevalence of impaired responsiveness to epinephrine in platelets among Japanese. Thromb Res 1996; 81: 85–90
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ariyoshi H, Kambayashi J, Ikeda M, Shinoki N, Kawasaki T, Monden M. Signal transduction system in epinephrine stimulated platelets; comparison between epinephrine sensitive and insensitive platelets. Thromb Res 1997; 85: 83–93
   PubMed Web of Science ®Google Scholar
• Pyo MK, Yun-choi HS, Hong YJ. Apparent heterogeneous responsiveness of human platelet rich plasma to catecholamines. Platelets 2003; 14: 171–178
   PubMed Web of Science ®Google Scholar
• Kim JM, Koo YK, Heo JE, Park S, Yun-choi HS. Reduced GPIIb/IIIa expression in platelets hyposensitive to catecholamines when activated with TRAP. Thromb Res 2009; 124: 90–95
   PubMed Web of Science ®Google Scholar
• Nakahashi TK, Kambayashi J, Nakamura T, Le SN, Yoshitake M, Tandon NN, Sun B. Platelets in Nonresponders to epinephrine stimulation showed reduced response to ADP. Thromb Res 2001; 104: 127–135
   PubMed Web of Science ®Google Scholar
• Redlich H, Vickers J, Lösche W, Heptinstall S, Kehrel B, Spangenberg P. Formation of platelet–leukocyte conjugates in whole blood. Platelets 1997; 8: 419–425
   PubMed Web of Science ®Google Scholar
• McNicol A. Platelet preparation and estimation of functional response. Platelets-A Practical Approach, SP Watson, KS Authi. Oirl Press, Axford University Press, London 1996; 1–13
   Google Scholar
• Boo YC, Tressel SL, Jo H. An improved method to measure nitrate/nitrite with an NO-selective electrochemical sensor. Nitric oxide 2007; 16: 306–312
   PubMed Web of Science ®Google Scholar
• Ignarro LJ, Fukuto JM, Griscavage JM, Rogers NE, Byrns RE. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: Comparison with enzymatically formed nitric oxide from L-arginine. Proc Natl Acad Sci 1993; 90: 8103–8107
   PubMed Web of Science ®Google Scholar
• Tsikas D. Methods of quantitative analysis of the nitric oxide metabolites nitrite and nitrate in human biological fluids. Free Radic Res 2005; 39: 797–815
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA, Libby P. Pathophysiology and management: Diabetes and atherosclerosis: epidemiology. J Am Med Assoc 2002; 287: 2570–2581
   PubMed Web of Science ®Google Scholar
• Ouviña SM, La Greca RD, Zanaro NL, Palmer L, Sassetti B. Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res 2001; 102: 107–114
   PubMed Web of Science ®Google Scholar
• Fateh-Moghadam S, Htun P, Tomandl B, Sander D, Stellos K, Geisler T, Langer H, Walton K, Handschu R, Garlichs C, et al. Hyperresponsiveness of platelets in ischemic stroke. Thromb Haemost 2007; 97: 974–978
   PubMed Web of Science ®Google Scholar
• Gawaz M, Bogner C. Changes in platelet membrane glycoproteins and platelet-leukocyte interaction during hemodialysis. Clin Investig 1994; 72: 424–429
   PubMedGoogle Scholar
• Ehlers R, Ustinov V, Chen Z, Zhang X, Rao R, Luscinskas FW, Lopez J, Plow E, Simon DI. Targeting Platelet–Leukocyte Interactions: Identification of the integrin Mac-1 binding site for the platelet counter receptor glycoprotein Ib. J Exp Med 2003; 198: 1077–1088
   PubMed Web of Science ®Google Scholar
• Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533–1537
   PubMed Web of Science ®Google Scholar
• Hagberg IA, Lyberg T. Evaluation of circulating platelet-leukocyte conjugates: A sensitive flow cytometric assay well suited for clinical studies. Platelets 2000; 11: 151–160
   PubMed Web of Science ®Google Scholar
• Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ. Increased circulating platelet-leukocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115: 451–459
   PubMed Web of Science ®Google Scholar
• Wun T, Cordoba M, Rangaswami A, Cheung AW, Paglieroni T. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol 2002; 24: 81–88
   PubMedGoogle Scholar
• Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523–530
   PubMed Web of Science ®Google Scholar
• Evangelista V, Manarini S, Sideri R, Rotondo S, Martelli N, Piccoli A, Totani L, Piccardoni P, Vestweber D, De Gaetano G, Cerletti C. Platelet/polymorpho-nuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: Role of PSGL-1 as a signaling molecular. Blood 1999; 93: 876–885
   PubMed Web of Science ®Google Scholar
• Li N, Hu H, Lindqvist M, Wikstrom-jonsson E, Goodall AH, Hjemdahl P. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20: 2702–2708
   PubMed Web of Science ®Google Scholar
• Mcever RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001; 86: 746–756
   PubMed Web of Science ®Google Scholar
• Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166–2171
   PubMed Web of Science ®Google Scholar
• Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498–511
   PubMed Web of Science ®Google Scholar
• Goubareva I, Gkaliagkousi E, Shah A, Queen L, Ritter J, Ferro A. Age decreases nitric oxide synthesis and responsiveness in human platelets and increases formation of monocyte-platelet aggregates. Cardiovasc Res 2007; 75: 793–802
   PubMed Web of Science ®Google Scholar
• Scholz T, Zhao L, Temmler U, Bath P, Heptinstall S, Losche W. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets 2002; 13: 401–406
   PubMed Web of Science ®Google Scholar
• Caron A, Théorêt JF, Mousa SA, Merhi Y. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils. J Cardi Pharm 2002; 40: 296–306
   PubMed Web of Science ®Google Scholar
• Michelson AD, Benoit SE, Furman MI, Breckwoldt WL, Rohrer MJ, Barnard MR, Loscalzo J. Effects of endothelium-derived relaxing factor/nitric oxide on platelet surface glycoproteins. Am J Physiol 1996; 270: H1640–H1648
   PubMedGoogle Scholar
• Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100: 350–356
   PubMed Web of Science ®Google Scholar
• Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C, Wagner K, Labugger R, Kelmi M, Noll G, Rulicke T, et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci 2000; 97: 11609–11613
   PubMed Web of Science ®Google Scholar
• Minamino T, Kitakaze M, Sato H, Asanuma H, Funaya H, Koretsune Y, Hori M. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol 1997; 17: 3191–3195
   PubMed Web of Science ®Google Scholar
• Yoon Y, Sonh J, Hong SH, Kim JQ. Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clinic Chem 2000; 46: 1626–1630
   PubMed Web of Science ®Google Scholar
• Levenson J, Pernollet MG, Iliou MC, Devynck MA, Simon A. Cyclic GMP release by acute enhanced external counterpulsation. Am J Hypertens 2006; 19: 867–72
   PubMed Web of Science ®Google Scholar
• Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000; 101: 2144–2148
   PubMed Web of Science ®Google Scholar
• Liu JL, Zucker IH. Regulation of sympathetic nerve activity in heart failure: A role for nitric oxide and angiotensin II. Circ Res 1999; 84: 417–423
   PubMed Web of Science ®Google Scholar
• Lefer AM, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Cardiovasc Res 1996; 32: 743–751
   PubMed Web of Science ®Google Scholar
• Radomki MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci 1990; 87: 5193–5197
   PubMed Web of Science ®Google Scholar
• Moncada S, Palmer RM. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Res 1991; 43: 109–141
   Google Scholar
• Schmidt HH, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta 1993; 1178: 153–175
   PubMed Web of Science ®Google Scholar
• Antl M, von Brühl ML, Eiglsperger C, Werner M, Konrad I, Kocher T, Wilm M, Hofmann F, Massberg S, Schlossmann J. IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation. Blood 2007; 109: 552–559
   PubMed Web of Science ®Google Scholar
• Gkaliagkousi E, Corrigall V, Becker S, Winter P, Shah A, Zamboulis C, Ritter J, Ferro A. Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. Eur Heart J Aug 17, 2009, [Epub ahead of print]
   PubMed Web of Science ®Google Scholar